This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Current Discounted Rates End In:

  • 00
  • 00
  • 00
  • 00
Delivered as Hybrid Event from September 20-30, 2021
Live In-Person Experience Delivered September 20-23Boston Convention and Exhibition Center

Annie De Groot, M.D.
Founder, CEO and CSO at Epivax, Inc.


Dr. Annie De Groot earned a BA from Smith College and her M.D. from Pritzker School of Medicine at the University of Chicago. After vaccinology training under Russell Howard (NIAID Laboratory of Parasitic Diseases) and Jay Berzofsky (National Cancer Institute), and training in Infectious Diseases at Tufts New England Medical Center, De Groot joined the faculty of Brown Medical School. In 1998 she founded EpiVax, Inc. In collaboration with EpiVax’s cofounder Bill Martin and colleague Lenny Moise, Dr. De Groot developed and validated a set of immunoinformatics tools that bring new insights to bear on the human immune response to pathogens and vaccines including COVID-19. Dr. De Groot is a research professor at the University of Georgia Center for Vaccines and Immunology, and volunteers as medical director of Clinica Esperanza/Hope Clinic, and scientific director at GAIA Vaccine Foundation.

Agenda Sessions

  • The PANDA Approach to Immunogenicity Assessment for New Drugs and Generic ANDAs

  • Developing a Highly Conserved, Non-human-like, and Cross-reactive SARS-CoV-2 Peptide-based COVID-19 Vaccine